NasdaqGS:KPTIBiotechs
Karyopharm Therapeutics (KPTI) Quarterly Loss Deepens Reinforcing Bearish Profitability Concerns
Karyopharm Therapeutics (KPTI) has opened Q1 2026 earnings season with revenue of about US$34.1 million in Q4 2025 and a basic EPS loss of US$5.71, providing a clear snapshot of a business still investing heavily for growth. Over recent quarters the company has seen revenue move between US$30.0 million and US$44.0 million, while basic EPS losses have ranged from roughly US$2.77 to US$5.71. This gives a tangible sense of how top line and per share results have been tracking into the latest...